Seeking Alpha

TG Therapeutics granted Orphan Drug Designation for Ublituximab

TG Therapeutics (TGTX +3.8%) pops after being granted an Orphan Drug Designation for Ublituximab, a treatment for extranodal marginal zone lymphoma.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs